EXCLUSIVE: Plus Therapeutics Lead Candidate Shows Preliminary Safety, Efficacy In Type Of Brain Cancer
Portfolio Pulse from Vandana Singh
Plus Therapeutics Inc reported preliminary safety and efficacy data from the ReSPECT-LM study evaluating its lead radiotherapeutic, rhenium (186Re) obisbemeda, for leptomeningeal metastases (LM). The data showed no dose-limiting toxicities and a decrease in CSF tumor cell counts by up to 91%. The FDA has approved continued dose escalation. However, PSTV shares are down 7.99% premarket.
August 11, 2023 | 10:00 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Plus Therapeutics' lead candidate shows preliminary safety and efficacy in a brain cancer study. Despite positive news, PSTV shares are down 7.99% premarket.
The positive results from the study indicate potential future success for Plus Therapeutics' lead candidate. However, despite this positive news, the company's shares are down in premarket trading, indicating a negative short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100